Ko HH, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 5
Paginas: 311-312
Archivo PDF: 86.54 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Zeuzen S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48(2): 407-17.

2. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telparevir (VX-950) and peginterferon alfa-2b in patients with hepatitis C. Hepatology 2007; 46(3): 640-8.

3. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49(2): 163-9.

4. Kwo P, et al. Interim Results From HCV Sprint-1: RVR/EVR From Phase 2 Study Of Boceprevir Plus Pegintron™ (Peginterferon Alfa-2b)/Ribavirin In Treatment Naive Subjects With Genotype-1 CHC. Journal of Hepatology 2008; 48, Supplement 2 (Abstracts of the 43rd annual meetings of the EASL): S372.

5. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008. 48(2): 385-97.